Pasithea Therapeutics Corp. Files 8-K with Material Agreement
Ticker: KTTAW · Form: 8-K · Filed: May 7, 2025 · CIK: 1841330
Sentiment: neutral
Topics: material-agreement, filing, financials
TL;DR
Pasithea Therapeutics Corp. signed a new deal, filed financials, and made an FD disclosure on May 6, 2025.
AI Summary
On May 6, 2025, Pasithea Therapeutics Corp. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial statements and exhibits. The filing details are associated with accession number 0001213900-25-040725.
Why It Matters
This 8-K filing indicates a significant event for Pasithea Therapeutics Corp., likely involving a new contract or partnership that could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the nature of this agreement is not fully detailed in the provided excerpt, necessitating caution.
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — Registrant
- May 6, 2025 (date) — Earliest event reported
- 0001213900-25-040725 (accession_number) — Filing identifier
FAQ
What type of material definitive agreement did Pasithea Therapeutics Corp. enter into?
The provided excerpt does not specify the exact nature of the material definitive agreement, only that one was entered into on May 6, 2025.
What is the accession number for this 8-K filing?
The accession number for this filing is 0001213900-25-040725.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 6, 2025.
What is the principal executive office address for Pasithea Therapeutics Corp.?
The principal executive office address is 1111 Lincoln Road, Suite 500, Miami Beach, FL 33139.
What are the key items reported in this 8-K filing?
The key items reported are Entry into a Material Definitive Agreement, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 7, 2025 regarding Pasithea Therapeutics Corp. (KTTAW).